Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Efamed Plus - Philippines FDA Drug Approval Details

Approvals/Philippines FDA/Efamed Plus

Approved

STANDARD

Efamed Plus

Lloyd Laboratories, Inc.🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: dee7db55b2d896a3
Company: Lloyd Laboratories, Inc.
Type: Standard

Approval Details

Approval Id: dee7db55b2d896a3
Drug Approval Philippines Name: Efamed Plus
Product Name: Efamed Plus
Registration Number: DR-XY27288
Brand Name: Efamed Plus
Generic Name: Guaifenesin + Salbutamol
Dosage Form: Syrup
Dosage Strength: 50mg/ 1mg per 5mL
Manufacturer: Lloyd Laboratories, Inc.
Trader: Medhaus Pharma, Inc.
Issuance Date: 28 December 2021
Expiry Date: 08 February 2027
Pharmacologic Category: Expectorant/Selective beta-2-adrenoreceptor
Classification: Prescription Drug (Rx)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

dee7db55b2d896a3

Type

Standard

Back to Philippines FDA Approvals